Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Single cell tracking reveals that Msh2 is a key component of an early-acting DNA damage-activated G2 checkpoint

Oncogene volume 22, pages 7642–7648 (2003)Cite this article

Abstract

Dysfunction of cell-cycle checkpoints in DNA mismatch repair (MMR)-deficient cells in response to DNA damage has implications for anticancer therapy and genetic instability. We have studied the cell-cycle effects of MMR deficiency (Msh2−/−) in primary mouse embryonic fibroblasts (MEFs) exposed to cisplatin (10 μ M × 1 h) using time-lapse microscopy. Kinetic responses of MEFs from different embryos and passage ages varied, but we report a consistent drug-induced inhibition of mitotic entry (approx. 50%). There was a loss of an early-acting (<5 h) delay in G2 to M transition in Msh2−/− cells, although a later-acting G2 arrest was apparently normal. This suggests that Msh2 primarily acts to delay mitotic entry of cells already in G2, that is, DNA damage incurred during G2 does not influence the cell once committed to mitotic traverse. Irrespective of Msh2 status, cisplatin treatment and the incurred DNA damage did not effect mitotic traverse or show any evidence for early (within 24 h) cell death. The results indicate that Msh2−/− status can result in the premature commitment to mitosis of a cell subpopulation, determined by the fraction residing in G2 at the time of damage induction. The findings suggest a new route to MMR-driven genetic instability that does not rely primarily on the integrity of the late-acting checkpoint.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Aebi S, Fink D, Gordon R, Kim HK, Zheng H, Fink VL and Howell SB . (1997). Clin. Cancer. Res., 3, 1763–1767.

  • Aquilina G, Crescenzi M and Bignami M . (1999). Carcinogenesis, 20, 2317–2326.

  • Bellacosa A . (2001). Cell Death Differ., 8, 1076–1092.

  • Branch P, Massson M, Aquilina G, Bignami M and Karran P . (2000). Oncogene, 19, 3138–3145.

  • Brown R, Hirst GL, Gallagher WM, Mcllwrath AJ, Margison GP, van der Zee AG and Anthoney DA . (1997). Oncogene, 15, 45–52.

  • Buermeyer AB, Deschenes SM, Baker SM and Liskay RM . (1999). Ann. Rev. Genet., 33, 533–564.

  • Christmann M and Kaina B . (2000). J. Biol. Chem., 275, 36256–36262.

  • Christmann M, Tomicic MT and Kaina B . (2002). Nucleic Acids Res., 30, 1959–1966.

  • de las Alas MM, Aebi S, Fink D, Howell SB and Los G . (1997). J. Natl. Cancer Inst., 89, 1537–1541.

  • Epstein RJ, Watson JV and Smith PJ . (1988). Cytometry, 9, 349–358.

  • Evans DL and Dive C . (1993). Cancer Res., 53, 2133–2139.

  • Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehré A, Christen RD and Howell SB . (1996). Cancer. Res., 56, 4881–4886.

  • Fink D, Aebi S and Howell SB . (1998). Clin. Cancer Res., 4, 1–6.

  • Fishel R, Lescoe MK, Rao MR, Copeland NF, Jenkings NA, Garber J, Kane M and Kolodner R . (1993). Cell, 75, 1027–1038.

  • Hartwell LH and Kastan MB . (1994). Science, 266, 1821–1828.

  • Hirose Y, Berger MS and Pieper RO . (2001). Cancer Res., 61, 1957–1963.

  • Karran P and Bignami M . (1999). DNA recombination and repair. Smith PJ, Jones CJ (eds). Oxford University Press: New York, pp. 66–98.

  • Kolodner RD . (1995). Trans. Biochem. Sci., 20, 397–401.

  • Kravtsov VD, Daniel TO and Koury MJ . (1999). Am. J. Pathol., 155, 1327–1339.

  • Lage H, Christmann M, Kern MA, Dietel M, Pick M, Kaina B and Schadendorf D . (1999). Int. J. Cancer, 80, 744–750.

  • Lin X, Ramamuthi K, Mishima M, Kondo A, Christen RD and Howell SB . (2001). Cancer Res., 15, 1508–1516.

  • Moreland NJ, Illand M, Kim YT, Paul J and Brown R . (1999). Cancer Res., 59, 2102–2106.

  • Nehme A, Baskaran R, Nebel S, Fink D, Howell SB, Wang JY and Christen RD . (1999). Br. J. Cancer, 79, 1104–1110.

  • Sansom OJ and Clarke AR . (2002). Oncogene, 21, 5934–5939.

  • Sansom OJ, Toft NJ, Winton J and Clark AR . (2001). Oncogene, 20, 3580–3584.

  • Sorenson CM and Eastman SA . (1988). Cancer Res., 48, 6703–6707.

  • Strathdee G, Sansom OJ, Sim A, Clarke AR and Brown R . (2001). Oncogene, 20, 1923–1927.

  • Therneau TM and Grambsch PM . (2000). Modeling Survival Data. Extending the Cox Model, Springer-Verlag: New York.

    Book  Google Scholar 

  • Toft NJ, Winton DJ, Kelly J, Howard LA, Dekker M, te Riele H, Arends MJ, Wyllie AH, Margison GP and Clarke AR . (1999). Proc. Natl. Acad Sci. USA, 96, 3911–3915.

  • Watson JV, Chambers SH and Smith PJ . (1987). Cytometry, 8, 1–8.

  • Xu B, Kim ST and Kastan MB . (2001). Mol. Cell. Biol., 21, 3445–3450.

  • Xu B, Kim ST, Lim DS and Kastan MB . (2002). Mol. Cell. Biol., 22, 1049–1059.

  • Yan T, Schupp JE, Hwang HS, Wagner MW, Berry SE, Strickfaden S, Veigl ML, Sedwick WD, Boothman DA and Kinsella TJ . (2001). Cancer Res., 61, 8290–8297.

  • Zindy F, Eishen CM, Randel DH, Kamijo T, Cleveland JL, Sherr CJ and Roussel MF . (1998). Genes Dev., 12, 2424–2433.

Download references

Acknowledgements

This work was partly supported by the AICR Amersham Bioscience pK and Kinetic Imaging Ltd.

Author information

Authors and Affiliations

  1. Department of Pathology, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, UK

    Nuria Marquez, Sally C Chappell & Paul J Smith

  2. Cardiff School of Bioscience, Cardiff University, Cardiff, CF10 3US, UK

    Owen J Sansom & Alan R Clarke

  3. Cancer Research Wales Laboratory, Velindre NHS Trust, Cardiff, CF14 2TL, UK

    Jon Court

  4. Department of Medical Biochemistry, University of Wales College of Medicine, Cardiff, UK

    Rachel J Errington

Authors
  1. Nuria Marquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sally C Chappell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Owen J Sansom
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alan R Clarke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jon Court
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rachel J Errington
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paul J Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul J Smith.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marquez, N., Chappell, S., Sansom, O. et al. Single cell tracking reveals that Msh2 is a key component of an early-acting DNA damage-activated G2 checkpoint. Oncogene 22, 7642–7648 (2003). https://doi.org/10.1038/sj.onc.1206876

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206876

Keywords

Search

Advanced search

Quick links